🔴 Neurosense Therapeutics is trading 9% down in pre-market with no identified company-specific catalyst

Neurosense Therapeutics is trading 9.00% lower at $4.35, with no new company-specific catalyst identified for the September 30 pre-market decline.

• The latest announcement was CFO Or Eisenberg’s participation in the September 29 ROTH Healthcare Opportunities Conference, where discussions were expected to cover PrimeC’s clinical and regulatory progress.
• The conference participation was not a newly announced financial or clinical milestone.
• Shares had also fallen in recent sessions, while the provided market indices were near flat and do not clearly explain the move.